Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology.
0/5 보강
APA
Zou M, Yang S, et al. (2026). Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology.. Annals of hepatology, 31(1), 102195. https://doi.org/10.1016/j.aohep.2026.102195
MLA
Zou M, et al.. "Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology.." Annals of hepatology, vol. 31, no. 1, 2026, pp. 102195.
PMID
41690671 ↗
같은 제1저자의 인용 많은 논문 (5)
- Immune Checkpoint Inhibitor-Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles.
- Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review.
- Advances in the near-infrared Ⅱ for in vivo fluorescence imaging applications: A review.
- Discovery and research progress of CDK8 inhibitors.
- Immune checkpoint inhibitors for patients with autoimmune bullous disease: Insights from a systematic review.